Two more for AtCor
Monday, 08 December, 2008
Medical device company AtCor has signed two new supply agreements worth US$1.5 million for its reflected blood pressure measurement system SphygmoCor.
The new agreements cap an excellent six months for the Sydney company, with supply contracts signed in the period worth US$5.7 million.
The device is aimed at both clinical practice and clinical trials to understand drug efficacy and mechanisms of action.
The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
